Pulmonary arterial hypertension related to human immunodeficiency virus infection: A case series

Table 1 Patients’ demographic and clinical characteristics at pulmonary hypertension diagnosis

Case No.	Age, yr	Gender	HIV risk factor	Duration of HIV infection previous to PAH, yr	CD4 count, cells/μL	HIV viral load, copies/mL	CDC stage	HAART	History of viral hepatitis	Other PAH risk factors	NYHA FC
1	25	F	IVDU	12	339	< 50	B3	No	Hep C	None	IV
2	39	F	IVDU	4	700	< 50	A1	No	Hep B + C	None	II
3	39	M	IVDU	11	460	< 50	B3	Yes	No	ASD	III
4	32	M	IVDU	12	500	< 50	B2	No	Hep C	ASD	III
5	43	M	UK	7	397	< 50	B3	Yes	No	Splenectomy without CTEPH	III
6	45	M	IVDU	8	332	< 50	B3	Yes	Hep B+C	Portal Hypertension	II
7	40	F	IVDU	22	517	< 50	C3	UK	Hep C	None	II
8	31	F	Hetero-sexual	1	444	< 50	A2	Yes	No	None	III
9	40	M	IVDU	22	900	3000	A1	No	Hep C	None	II
10	41	M	IVDU	21	772	308	A2	No	Hep C	None	II
11	40	M	IVDU	10	460	359810	A1	Yes	Hep C	Portal Hypertension	III
12	40	F	UK	5	46	114	C3	No	Hep C	Portal Hypertension	III
13	39	M	IVDU	10	1234	< 50	B1	Yes	Hep C	None	III
14	46	M	IVDU	14	411	< 50	A2	Yes	Hep C	Portal Hypertension	II
15	47	F	IVDU	14	800	< 50	A1	No	Hep C	ASD	III
16	47	M	IVDU	4	450	< 20	A2	Yes	Hep C	None	II
17	47	F	IVDU	23	760	< 20	C2	No	Hep B + C	Portal Hypertension	II
18	43	M	UK	19	NA	NA	A2	No	No	Portal Hypertension	III

ASD: Atrial septal defect; CDC: Centers for disease control; CTEPH: Chronic thromboembolic pulmonary hypertension; F: Female; M: Male; HAART: Highly active anti-retroviral therapy; HIV: Human immunodeficiency virus; IVDU: Intravenous drug use; NA: Not accessible; NYHA FC: New York heart association functional class; PAH: Pulmonary arterial hypertension; UK: Unknown.

Table 2 Patients’ follow-up data

Case No.	Actual status	Period of follow-up, yr	Year of PAH diagnosis	Initial specific therapy	Last visit specific therapy	Initial 6MWT (m)	Final 6MWT (m)	Variation on NYHA FC
1	Dead (cause: heart failure)	2.8	1998	Epoprostenol	Epoprostenol	211	463	0
2	Alive	11.3	2001	Treprostinil	Sildenafil	NA	669	-1
3	Alive	10.8	2001	Sildenafil	Sildenafil + Ambrisentan	512	630	-1
4	Alive	9.9	2002	Sildenafil	Sildenafil + Ambrisentan + Iloprost	516	570	-2
5	Alive	11.3	2001	Treprostinil	Sildenafil	313	414	0
6	Dead (cause: liver disease)	0.3	2005	Sildenafil	Sildenafil	400	NA	NA
7	Alive	7.0	2005	Ambrisentan	Ambrisentan + Sildenafil	435	473	0
8	Missing	3.9	2006	Sildenafil	Sildenafil	300	511	-2
9	Alive	5.3	2006	Sildenafil	Sildenafil	455	546	0
10	Alive	4.5	2007	Sildenafil	Tadalafil	650	703	0
11	Alive	8.5	2003	Treprostinil	Tadalafil	510	570	-2
12	Alive	8.8	2003	Iloprost	Ambrisentan	NA	450	-1
13	Alive	11.8	2000	Treprostinil	Bosentan	327	489	-1
14	Missing	0.4	2005	Sildenafil	Sildenafil	500	NA	0
15	Alive	3.5	2008	Sildenafil + Bosentan	Sildenafil + Bosentan + Iloprost	350	420	0
16	Alive	1.6	2010	Tadalafil	Tadalafil	525	570	0
17	Alive	1.4	2011	Ambrisentan	Ambrisentan	439	423	0
18	Alive	0.5	2011	Sildenafil	Sildenafil	537	600	0

6MWT: 6 min walk test; NYHA FC: New York heart association functional class; NA: Not accessible; PAH: Pulmonary arterial hypertension.